Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Effic... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascend... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant ... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safet... Read More
Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lu... Read More
U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662720) titled 'A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Nec... Read More
U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662369) titled 'CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haplo... Read More